Development of plant-made monoclonal antibodies against viral infections

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Current plant-based systems offer multiple advantages for monoclonal antibody (mAb) development and production beyond the traditional benefits of low cost and high scalability. Novel expression vectors have allowed the production of mAbs at high levels with unprecedented speed to combat current and future pandemics. Host glycoengineering has enabled plants to produce mAbs that have unique mammalian glycoforms with a high degree of homogeneity. These mAb glycovariants exhibit differential binding to various Fc receptors, providing a new way to optimize antibody effector function for improving mAb potency or safety. This review will summarize the status of anti-viral mAb development with plant-based systems. The preclinical and clinical development of leading plant-made mAb candidates will be highlighted. In addition, the remaining challenges and potential applications of this technology will be discussed.

Original languageEnglish (US)
Pages (from-to)148-160
Number of pages13
JournalCurrent opinion in virology
StatePublished - Feb 2022

ASJC Scopus subject areas

  • Virology


Dive into the research topics of 'Development of plant-made monoclonal antibodies against viral infections'. Together they form a unique fingerprint.

Cite this